

Leben Care and COSMOTEC, an M3 Group company announces strategic partnership, to bring AI powered Diabetic Retinopathy diagnostics in Japan Market

Leben Care and COSMOTEC partners to offer "Netra Screen" to Japan Market

Singapore - 19th June 2018 - Leben Care and COSMOTEC, are entering into an strategic partnership for the distribution of Leben Care's Netra.AI platform for the Japanese market. The partnership will strengthen Leben Care's position in Japan and help large number of patients with Diabetic Retinopathy.

"Our roadmap included sales of Artificial Intelligence powered medical device / software, which is still evolving in Japan. The product of Leben Care will be the first step for us. Diabetic retinopathy is the second leading cause of avoidable blindness in adults, and it is the mostly prevalent in the 50s to 60s age group in Japan. Early detection and early treatment are important" says Mr. Takesue, CEO of COSMOTEC. "On the other hand, in Japan, non-specialists are the first checker of the disease, so there is a risk to oversight. Leben Care products will play an important role in these scenario".

"Diabetes in Japan is growing at an alarming rate with a prevalence of 7.7 in the adult population. Preventing blindness and vision loss from diabetic retinopathy is a cause of concern globally and this partnership has come at the right time to establish a novel approach for screening of the diabetic population" says Theenathayalan Parthasarathy, Director & Chief Delivery Officer, Leben Care "AI powered screening and diagnostic tools can bring transformational improvements to the front lines of healthcare. We are thrilled to lead this era with a partner like COSMOTEC."

About M3, Inc.,

The M3 Group operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites which include mdlinx.com, m3.com, research.m3.com, Doctors.net.uk, medigate.net and medlive.cn and so on. M3 group has the largest news website for healthcare professionals, m3.com, and more than 80% of doctors in Japan are registered. M3 Inc., is a publicly traded company on the Tokyo Stock Exchange and its market cap is USD 13.086 billion (June, 2018), with subsidiaries in major markets including USA, Europe, Japan, S. Korea, China and India. The M3 Group provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices

in Japan, UK, France, Germany, Brazil, Sweden, China, India, and South Korea, as well as in the US. Please visit <https://corporate.m3.com/en/> for more information.

About COSMOTEC

COSMOTEC Co., Ltd. , established in 1992 specialises in sales and consulting of medical devices focussing on cardiac surgery , general surgery and endovascular treatment. COSMOTEC has 98% market share of the institutions conducting cardiovascular surgery in Japan. COSMOTEC has offices in Tokyo, Sapporo, Sendai, Nagoya, Osaka, Okayama and Fukuoka across Japan. COSMOTEC is an M3,Inc., group company. Please visit <http://cosmotec.com/english/> for more information.

About Netra.AI

Netra.AI platform provides valuable, automated, Clinical Insights on retina, blood vessels and lesions, aiding Primary care workers in providing supportive information to Ophthalmologist / retina specialist and other healthcare professionals using AI / Deep machine learning. The solutions enhance clinical assessments, treatment planning, and disease progression monitoring of patients with retina conditions, such as Diabetic Retinopathy, Glaucoma and Age Related Macular Degeneration.

About Leben Care

Leben Care Technologies Pte. Ltd., is an Artificial Intelligence (AI) Healthcare company based out of Singapore, focused on improving quality of diagnosis across the areas of life sciences. Leben Care's first flagship AI Platform Netra.AI uses cutting edge Algorithms with a 4 step Deep Convolutional Neural Network (DCNN). The algorithm is developed in guidance with some of the leading experts in Retina globally. Netra.AI enables automated and point of care Retinal Image Analysis by 1) Reducing incidence of blindness by timely identification of patients at risk and 2) Offering insights to medical practitioners thus enabling improved diagnostic outcome. Please visit www.leben.ai for more information.

For further information please contact
Mohammed Imran Akthar
Director & CTO
Leben Care Technologies Pte Ltd
imran@leben.ai